- Home
- RYTM vs PK Comparison
RYTM vs PK Comparison
Compare RYTM & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- PK
- Stock Information
- Founded
- RYTM 2008
- PK 1946
- Country
- RYTM United States
- PK United States
- Employees
- RYTM N/A
- PK N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- PK Real Estate Investment Trusts
- Sector
- RYTM Health Care
- PK Real Estate
- Exchange
- RYTM Nasdaq
- PK Nasdaq
- Market Cap
- RYTM 4.3B
- PK 2.1B
- IPO Year
- RYTM 2017
- PK N/A
- Fundamental
- Price
- RYTM $86.70
- PK $11.21
- Analyst Decision
- RYTM Strong Buy
- PK Hold
- Analyst Count
- RYTM 13
- PK 11
- Target Price
- RYTM $88.77
- PK $12.85
- AVG Volume (30 Days)
- RYTM 948.9K
- PK 3.8M
- Earning Date
- RYTM 08-05-2025
- PK 07-31-2025
- Dividend Yield
- RYTM N/A
- PK 12.48%
- EPS Growth
- RYTM N/A
- PK 45.67
- EPS
- RYTM N/A
- PK 0.61
- Revenue
- RYTM $136,863,000.00
- PK $2,602,000,000.00
- Revenue This Year
- RYTM $37.56
- PK $2.49
- Revenue Next Year
- RYTM $74.99
- PK $3.25
- P/E Ratio
- RYTM N/A
- PK $18.42
- Revenue Growth
- RYTM 48.88
- PK N/A
- 52 Week Low
- RYTM $40.61
- PK $8.27
- 52 Week High
- RYTM $94.80
- PK $16.23
- Technical
- Relative Strength Index (RSI)
- RYTM 76.93
- PK 62.34
- Support Level
- RYTM $64.65
- PK $10.50
- Resistance Level
- RYTM $94.80
- PK $11.49
- Average True Range (ATR)
- RYTM 3.47
- PK 0.33
- MACD
- RYTM 2.75
- PK 0.09
- Stochastic Oscillator
- RYTM 76.18
- PK 81.79
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.